Dr Reddys Laboratories (RDY) Cost of Revenue (2009 - 2026)

Dr Reddys Laboratories has reported Cost of Revenue for 18 years, with the latest figure at $455.9 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 5.96% year-over-year to $455.9 million in Q2 2026; TTM through Jun 2026 was $1.8 billion, a 9.56% increase from a year earlier, with the FY2026 full-year figure at $1.7 billion, up 6.96% from the prior year.
• Cost of Revenue was $455.9 million for Q2 2026 at Dr Reddys Laboratories, up from $453.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $457.6 million in Q3 2025, with the low at $329.0 million in Q4 2022.
• Average Cost of Revenue over 5 years is $384.8 million, with a median of $361.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue decreased 6.33% in 2022, then rose 23.51% in 2025.
• Over 5 years, Cost of Revenue stood at $329.0 million in 2022, then gained by 9.31% to $359.6 million in 2023, then climbed by 13.73% to $409.0 million in 2024, then grew by 11.09% to $454.4 million in 2025, then gained by 0.35% to $455.9 million in 2026.
• The last three Cost of Revenue figures came in at $455.9 million (Q2 2026), $453.7 million (Q1 2026), and $454.4 million (Q4 2025), per Business Quant data.